Tammy Rose is a Regulatory Affairs executive who holds more than sixteen years of experience in strategic management of the regulatory affairs process, leading teams and collaborating across functional areas to advance therapies across all stages. Tammy kicked off her regulatory career in 2001 at Amgen where she continually grew her strategic roles and responsibilities through the development and approval of denosumab (Prolia®/XGEVA®). Following her time at Amgen, Tammy served as the global regulatory leader at Genentech leading the regulatory team driving multiple initiatives for Lucentis® and subsequently responsible for the OCREVUS™ US licensing application. Tammy then served as a Senior Director at Halozyme Therapeutics where she led the team responsible for the late-stage investigational candidate PEGPH20. Tammy joined UNITY Biotechnology in June 2017 as the Vice President of Regulatory Affairs.